[go: up one dir, main page]

ITMI20061624A1 - Mono-coniugati sito-specifici di g-csf - Google Patents

Mono-coniugati sito-specifici di g-csf

Info

Publication number
ITMI20061624A1
ITMI20061624A1 IT001624A ITMI20061624A ITMI20061624A1 IT MI20061624 A1 ITMI20061624 A1 IT MI20061624A1 IT 001624 A IT001624 A IT 001624A IT MI20061624 A ITMI20061624 A IT MI20061624A IT MI20061624 A1 ITMI20061624 A1 IT MI20061624A1
Authority
IT
Italy
Prior art keywords
csf
site
conjugates
analogues
derivatives
Prior art date
Application number
IT001624A
Other languages
English (en)
Inventor
Gaetano Orsini
Rodolfo Schrepper
Mauro Sergi
Geoffrey Taylor
Giancarlo Tonon
Original Assignee
Bioker Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioker Srl filed Critical Bioker Srl
Priority to IT001624A priority Critical patent/ITMI20061624A1/it
Priority to JP2009524158A priority patent/JP5336372B2/ja
Priority to PL07788029T priority patent/PL2049566T3/pl
Priority to US12/310,003 priority patent/US7893019B2/en
Priority to CA002660615A priority patent/CA2660615A1/en
Priority to PCT/EP2007/057824 priority patent/WO2008017603A1/en
Priority to AT07788029T priority patent/ATE453666T1/de
Priority to DE602007004120T priority patent/DE602007004120D1/de
Priority to ES07788029T priority patent/ES2338605T3/es
Priority to EP07788029A priority patent/EP2049566B1/en
Publication of ITMI20061624A1 publication Critical patent/ITMI20061624A1/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/53Colony-stimulating factor [CSF]
    • C07K14/535Granulocyte CSF; Granulocyte-macrophage CSF
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
IT001624A 2006-08-11 2006-08-11 Mono-coniugati sito-specifici di g-csf ITMI20061624A1 (it)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IT001624A ITMI20061624A1 (it) 2006-08-11 2006-08-11 Mono-coniugati sito-specifici di g-csf
JP2009524158A JP5336372B2 (ja) 2006-08-11 2007-07-30 G−csf部位特異的モノコンジュゲート
PL07788029T PL2049566T3 (pl) 2006-08-11 2007-07-30 Swoiste dla miejsca monokoniugaty G-CSF
US12/310,003 US7893019B2 (en) 2006-08-11 2007-07-30 G-CSF site-specific mono-conjugates
CA002660615A CA2660615A1 (en) 2006-08-11 2007-07-30 G-csf site-specific mono-conjugates
PCT/EP2007/057824 WO2008017603A1 (en) 2006-08-11 2007-07-30 G-csf site-specific mono-conjugates
AT07788029T ATE453666T1 (de) 2006-08-11 2007-07-30 Spezifische monokonjugate von g-csf
DE602007004120T DE602007004120D1 (de) 2006-08-11 2007-07-30 Spezifische monokonjugate von g-csf
ES07788029T ES2338605T3 (es) 2006-08-11 2007-07-30 Monoconjugados especificos de sitio de g-csf.
EP07788029A EP2049566B1 (en) 2006-08-11 2007-07-30 G-csf site-specific mono-conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001624A ITMI20061624A1 (it) 2006-08-11 2006-08-11 Mono-coniugati sito-specifici di g-csf

Publications (1)

Publication Number Publication Date
ITMI20061624A1 true ITMI20061624A1 (it) 2008-02-12

Family

ID=38510395

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001624A ITMI20061624A1 (it) 2006-08-11 2006-08-11 Mono-coniugati sito-specifici di g-csf

Country Status (10)

Country Link
US (1) US7893019B2 (it)
EP (1) EP2049566B1 (it)
JP (1) JP5336372B2 (it)
AT (1) ATE453666T1 (it)
CA (1) CA2660615A1 (it)
DE (1) DE602007004120D1 (it)
ES (1) ES2338605T3 (it)
IT (1) ITMI20061624A1 (it)
PL (1) PL2049566T3 (it)
WO (1) WO2008017603A1 (it)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
US7803777B2 (en) * 2003-03-14 2010-09-28 Biogenerix Ag Branched water-soluble polymers and their conjugates
JP4674702B2 (ja) 2003-04-09 2011-04-20 バイオジェネリクス エージー グリコペギレ−ション法およびその方法により生成されたタンパク質/ペプチド
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
MXPA05011832A (es) * 2003-05-09 2006-02-17 Neose Technologies Inc Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
WO2005012484A2 (en) * 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
MXPA06005732A (es) * 2003-11-24 2006-08-17 Neose Technologies Inc Eritropoyetina glucopegilada.
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
KR101237884B1 (ko) * 2003-12-03 2013-02-27 바이오제너릭스 에이지 글리코 peg화 과립구 콜로니 자극인자
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1694351A2 (en) * 2003-12-03 2006-08-30 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
US7338933B2 (en) * 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
US20090292110A1 (en) * 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
EP1799249A2 (en) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
DK2586456T3 (en) 2004-10-29 2016-03-21 Ratiopharm Gmbh Conversion and glycopegylation of fibroblast growth factor (FGF)
AU2006203792B2 (en) * 2005-01-10 2011-11-03 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20110003744A1 (en) * 2005-05-25 2011-01-06 Novo Nordisk A/S Glycopegylated Erythropoietin Formulations
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080248959A1 (en) * 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー/エス ポリペプチドコンジュゲートの精製方法
MX2009003470A (es) * 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
JP2010523582A (ja) * 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト グリコpeg化g−csfを用いた治療方法
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
CA2690611C (en) * 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
US7968811B2 (en) * 2007-06-29 2011-06-28 Harley-Davidson Motor Company Group, Inc. Integrated ignition and key switch
DE202008017456U1 (de) 2007-08-27 2009-08-27 Biogenerix Ag Flüssig-Formulierung von G-CSF-Konjugaten
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2242505A4 (en) * 2008-01-08 2012-03-07 Biogenerix Ag GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
JP5619630B2 (ja) 2008-02-27 2014-11-05 ノボ・ノルデイスク・エー/エス 結合型第viii因子分子
MX2011000859A (es) * 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
IT1392655B1 (it) * 2008-11-20 2012-03-16 Bio Ker S R L Site-specific monoconjugated insulinotropic glp-1 peptides.
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2734238B1 (en) 2011-07-19 2020-02-19 CellMosaic, Inc. Sugar alcohol-based crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof
ITMI20122097A1 (it) * 2012-12-10 2014-06-11 Bio Ker S R L Procedimento per la preparazione di proteine terapeutiche peghilate ad elevato grado di purezza
EP3050570A1 (en) 2015-01-31 2016-08-03 Neurovision Pharma GmbH Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
CN112316120A (zh) * 2019-08-05 2021-02-05 天津派格生物技术有限公司 使用低动员型g-csf有效且安全治疗粒细胞减少症的方法
TR201917122A2 (tr) * 2019-11-05 2021-05-21 Hacettepe Ueniversitesi Protei̇n i̇laçlarin enzi̇mati̇k yolla bi̇yopoli̇merlerle konjugasyonu
WO2021188869A2 (en) * 2020-03-20 2021-09-23 Amgen Inc. Determination of free n-terminus of pegfilgrastim using an acid protease
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
WO1996010089A1 (fr) * 1994-09-29 1996-04-04 Ajinomoto Co., Inc. Modification d'un peptide et d'une proteine
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE60004172T2 (de) 1999-01-29 2004-04-22 F. Hoffmann-La Roche Ag Gcsf konjugate
DE10011926A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Genetisch veränderte Fibroblastenzellen
NZ530545A (en) * 2001-07-11 2006-10-27 Maxygen Holdings Ltd Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
WO2004101619A1 (ja) * 2003-05-15 2004-11-25 Shionogi Co., Ltd. 機能的糖ペプチドの合理的設計および合成
EP1586334A1 (en) 2004-04-15 2005-10-19 TRASTEC scpa G-CSF conjugates with peg
EP1768700B1 (en) 2004-07-16 2010-12-15 Nektar Therapeutics Conjugates comprising gm-csf and a polymer

Also Published As

Publication number Publication date
WO2008017603A1 (en) 2008-02-14
PL2049566T3 (pl) 2010-06-30
JP2010500390A (ja) 2010-01-07
US20100029555A1 (en) 2010-02-04
DE602007004120D1 (de) 2010-02-11
CA2660615A1 (en) 2008-02-14
US7893019B2 (en) 2011-02-22
EP2049566B1 (en) 2009-12-30
ES2338605T3 (es) 2010-05-10
ATE453666T1 (de) 2010-01-15
JP5336372B2 (ja) 2013-11-06
EP2049566A1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
ITMI20061624A1 (it) Mono-coniugati sito-specifici di g-csf
AU2016218977B2 (en) Nucleic acid products and methods of administration thereof
EP3211001A3 (en) Superagonists and antagonists of interleukin-2
AU2018274216A1 (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
BRPI0508424A (pt) muteìnas de interleucina-2 melhoradas
UA103221C2 (uk) Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини
ATE468862T1 (de) G-csf konjugate
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
TR201903587T4 (tr) Telomeraz aktivitesinin artırılması için bileşimler.
EA200702487A1 (ru) Пегилированные соединения glp-1
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
MY150739A (en) Four branched dendrimer-peg for conjugation to proteins and peptides
BRPI0717441B8 (pt) composto, medicamento, e, uso do derivado de metastina
EA201500261A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7
ATE308545T1 (de) Chlorophyll- und bacteriochlorophyllester, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
CN1960766A (zh) 新的g-csf轭合物
KR100735784B1 (ko) 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CN1911447A (zh) 转铁蛋白-聚乙二醇-药物分子复合物及其用途
Bradstock The use of hematopoietic growth factors in the treatment of acute leukemia
ZA202207211B (en) Peptide docking vehicle for targeted nucleic acid delivery
EA201101663A1 (ru) Ковалентный конъюгат полиэтиленгликоля с гранулоцитарным колониестимулирующим фактором человека
Sergi et al. Enzymatic techniques for PEGylation of biopharmaceuticals
Valent et al. Why clinicians should be interested in interleukin-3
CN101711876A (zh) 一种聚乙二醇修饰的重组人粒细胞集落刺激因子及其制备方法